Clinical trial
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
NCT03258554 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 3, 2018
- Completion date
- September 4, 2025
- Enrollment
- 196 (actual)
- Sites
- 256
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, head and neck squamous cell carcinoma, hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharyngeal squamous cell carcinoma, pathologic stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, squamous cell carcinoma of unknown primary, stage iii hypopharyngeal carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iva hypopharyngeal carcinoma ajcc v8, stage iva laryngeal cancer ajcc v8, stage iva lip and oral cavity cancer ajcc v8, stage iva oropharyngeal (p16-negative) carcinoma ajcc v8, stage ivb hypopharyngeal carcinoma ajcc v8, stage ivb laryngeal cancer ajcc v8, stage ivb lip and oral cavity cancer ajcc v8, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8